Preoperative CA19‐9 and CEA were assessed within the normal range in the majority of patients [85 (74.6%) and 99 (86.8%), respectively], but tumor size and differentiation varied significantly among GBC patients, with tumors of 1–3 cm [57 (50.0%)] and well differentiation [54 (47.4%)] being the most prevalent. This evidence concerns the gene CEACAM5 and neoplasm.